Fosun Pharma Gets Nod to Trial Alopecia Drug in US

MT Newswires Live

2025/05/12

Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit, Shanghai MicroH Therapeutics, will conduct a phase I clinical trial on LBP-ShC4 in the US after receiving approval from the US Food and Drug Administration, according to a Hong Kong Stock Exchange filing on May 9.

The drug is intended to be used for the treatment of androgenetic alopecia, the filing said.

The Chinese pharmaceutical company invested 17 million yuan in the research and development of the drug as of April.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2534209262"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534209262\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534209262?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-12 11:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534209262","market":"fut","top_or_hot":-1,"title":"Fosun Pharma Gets Nod to Trial Alopecia Drug in US","media":"MT Newswires Live","content":"<html><body><p> Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit, Shanghai MicroH <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, will conduct a phase I clinical trial on LBP-ShC4 in the US after receiving approval from the US Food and Drug Administration, according to a Hong Kong Stock Exchange filing on May 9.</p><p>The drug is intended to be used for the treatment of androgenetic alopecia, the filing said.</p><p>The Chinese pharmaceutical company invested 17 million yuan in the research and development of the drug as of April.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Gets Nod to Trial Alopecia Drug in US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Gets Nod to Trial Alopecia Drug in US\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-05-12 11:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit, Shanghai MicroH <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, will conduct a phase I clinical trial on LBP-ShC4 in the US after receiving approval from the US Food and Drug Administration, according to a Hong Kong Stock Exchange filing on May 9.</p><p>The drug is intended to be used for the treatment of androgenetic alopecia, the filing said.</p><p>The Chinese pharmaceutical company invested 17 million yuan in the research and development of the drug as of April.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600196","symbol_name":"復星醫藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2534209262","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534209262","pubTimestamp":1747022063,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical's  unit, Shanghai MicroH Therapeutics, will conduct a phase I clinical trial on LBP-ShC4 in the US after receiving approval from the US Food and Drug Administration, according to a Hong Kong Stock Exchange filing on May 9.The drug is intended to be used for the treatment of androgenetic alopecia, the filing said.The Chinese pharmaceutical company invested 17 million yuan in the research and development of the drug as of April.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0012":"证金概念","BK1593":"医美概念股","BK0175":"白马股","BK0196":"行业龙头","BK0183":"MSCI概念","BK0060":"抗癌","BK0187":"一线龙头","00656":"复星国际","BK1230":"工业集团企业","02196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0096":"民营医院","BK1191":"制药","BK1515":"抗疫概念","BK0188":"融资融券"},"translate_title":"复星医药获准在美国试验脱发药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":1,"02196":0.9},"content_text":"Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit, Shanghai MicroH Therapeutics, will conduct a phase I clinical trial on LBP-ShC4 in the US after receiving approval from the US Food and Drug Administration, according to a Hong Kong Stock Exchange filing on May 9.The drug is intended to be used for the treatment of androgenetic alopecia, the filing said.The Chinese pharmaceutical company invested 17 million yuan in the research and development of the drug as of April.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}